Clinicopathological analysis of mediastinal large B-cell lymphoma and classical Hodgkin lymphoma of the mediastinum

Leukemia and Lymphoma

Volumn 54, Issue 5, 2013, Pages 967-972

  Yamamoto, Wataru ^a   Nakamura, Naoya ^b   Tomita, Naoto ^c   Ishii, Yoshimi ^a   Takasaki, Hirotaka ^a   Hashimoto, Chizuko ^a   Motomura, Shigeki ^a   Yamazaki, Etsuko ^c   Ohshima, Rika ^d   Numata, Ayumi ^e   Ishigatsubo, Yoshiaki ^c   Sakai, Rika ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e Fujisawa City Hospital   (Japan)

Author keywords

Nodular sclerosis classical Hodgkin lymphoma; PDL1; Primary mediastinal large B cell lymphoma

Indexed keywords

BLEOMYCIN; CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; VINBLASTINE; VINCRISTINE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FIBROSIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOMA; MALE; MEDIASTINUM; NODULAR SCLEROSING CLASSICAL HODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT TRANSPORT; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD20; ANTIGENS, SURFACE; DATABASES, FACTUAL; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA, B-CELL; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84876220267     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.733881     Document Type: Article

References (20)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press; 2008. pp 250-251, 330.
2. Cazals-Hatem D, Lepaqe E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 non-mediastinal large B-cell lymphoma, a GELA (" Groupe d'Etude des Lymphomes de I'Adulte") study. Am J Surg Pathol 1996;20: 877-888.
3. Moldenhauer G, Popov SW, Wotschke B, et al. AID expression identif es interfollicular large B cell as putative precursors of mature B-cell malignancies. Blood 2006;107:2470-2473.
4. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma Differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879.
5. Colby TV, Hoppe RT, Warnke RA. Hodgkin's disease: a clinicopathologic study of 659 cases. Cancer 1982;49:1848-1858.
6. Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003; 162: 243-253.
7. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identif es a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 6: 851-862.
8. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000; 50:696-702.
9. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011; 118: 2659-2669.
10. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9q24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2011; 116: 3268-3277.
11. Hans CP, Weisenburger DD, Greiner TC, et al. Conformation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282.
12. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classif es diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.
13. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
14. Carbone PP, Kaplan HS, Musshof K, et al. Report of the committee on Hodgkin's disease staging classifcation. Cancer Res 1971;31: 1860-1861.
15. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-3113.
16. Higgins JP, Warnke RA. CD30 expression is common in medias-tinal large B-cell lymphoma. Am J Clin Pathol 1999;112:241-247.
17. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma Differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879.
18. Gruss HJ, Boiani N, Williams DE, et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 1994;83:2045-2056.
19. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008;111:3220-3224.
20. Johnson NA, Boyle M, Bashashati A, et al. diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood 2009;113:3773-3780.